|
Volumn 14, Issue 18, 2000, Pages 2946-2948
|
Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy [5]
a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
AMPHOTERICIN B LIPID COMPLEX;
ANTIRETROVIRUS AGENT;
DIDANOSINE;
INDINAVIR;
LAMIVUDINE;
MEGLUMINE ANTIMONATE;
NELFINAVIR;
RITONAVIR;
SAQUINAVIR;
STAVUDINE;
ZIDOVUDINE;
ADULT;
CLINICAL ARTICLE;
FEMALE;
FOLLOW UP;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LEISHMANIA;
LETTER;
LYMPHOCYTE COUNT;
MALE;
PRIORITY JOURNAL;
PROPHYLAXIS;
RELAPSE;
SUPERINFECTION;
TREATMENT OUTCOME;
VISCERAL LEISHMANIASIS;
ADULT;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
AMPHOTERICIN B;
ANIMALS;
ANTIPROTOZOAL AGENTS;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
CHEMOPREVENTION;
FEMALE;
HIV INFECTIONS;
HUMANS;
LEISHMANIA INFANTUM;
LEISHMANIASIS, VISCERAL;
LIPOSOMES;
MALE;
MEGLUMINE;
MIDDLE AGED;
ORGANOMETALLIC COMPOUNDS;
RECURRENCE;
TREATMENT OUTCOME;
|
EID: 0034524617
PISSN: 02699370
EISSN: None
Source Type: Journal
DOI: 10.1097/00002030-200012220-00020 Document Type: Letter |
Times cited : (64)
|
References (10)
|